Front Row with BioCentury: Wake up to China’s first-in-class innovation

Innovation in China is rapidly progressing from fast follower to first in class. In the debut episode of Front Row with BioCentury, a new subscriber-only series bringing deeper insights into BioCentury’s analysis of hot topics in biopharma, Head of Discovery and Translation Karen Tkach Tuzman discusses China’s innovation surge in dealmaking, early-stage R&D and preclinical publications.

In this in-depth interview, Tkach Tuzman draws connections across the various threads of analysis, putting context around the reasons behind the rush to partner with China biotechs, the way innovators in China are using their systemic advantages to generate first-in-human data fast, and perhaps most underappreciated of all, the amount of first-order innovation coming from China’s academic and research labs. ...